The Journal of Headache and Pain (Dec 2019)

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

  • Stephen D. Silberstein,
  • Virginia L. Stauffer,
  • Katie A. Day,
  • Sarah Lipsius,
  • Maria-Carmen Wilson

DOI
https://doi.org/10.1186/s10194-019-1069-x
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 2

Abstract

Read online

After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.